[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525247":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":32,"responsibleParty":53,"collaborators":19,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":19,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":19,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":34,"whyStopped":19,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Chinese PLA General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"EBV-TCR-T cells","EXPERIMENTAL","Phase 1 trail:\n\nThe patients with EBV infection after HSCT will receive one to three infusions of donor-derived EBV-TCR-T cells, with the escalated dose ranging from 5×10\\^5\u002Fkg to 1×10\\^6\u002Fkg EBV-TCR-T cells per dose.\n\nPhase 2 trail:\n\nAccording to the PK and response data, the dose escalation phase will be carried out.",[13],"Biological: EBV-TCR-T cells",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","The patients with EBV infection after HSCT will receive one to three infusions of donor-derived EBV-TCR-T cells, with the escalated dose ranging from 5×10\\^5\u002Fkg to 1×10\\^6\u002Fkg EBV-TCR-T cells per dose.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Daihong Liu, Doctor","PRINCIPAL_INVESTIGATOR",[25,29],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","+86 18301339032","daihongrm@163.com",{"name":30,"role":26,"phone":31,"phoneExt":19,"email":19},"Liping Dou, Doctor","+86 13681207138",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Beijing","Beijing Municipality","100853","China","CN",{"type":41,"coordinates":42},"Point",[43,44],116.39723,39.9075,{"lat":44,"lon":43},[47,49,52],{"name":22,"role":26,"phone":48,"phoneExt":19,"email":28},"86-13681171597",{"name":30,"role":26,"phone":50,"phoneExt":19,"email":51},"86-13681207138","lipingruirui@163.com",{"name":22,"role":23,"phone":19,"phoneExt":19,"email":19},{"type":23,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Daihong Liu","Director","100525247","phase-1-clinical-study-of-ebv-tcr-t-cells-for-ebv-infection-after-allogenic-hsct-100525247",false,"NCT06119256","Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT","Multicenter, Open Label, Single-arm Exploratory Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT","Inclusion Criteria:\n\n* Age 14-75 years, gender unlimited.\n* Diagnosed with hematologic malignancies and have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT), with EBV infection after allo-HSCT.\n* Karnofsky Score ≥ 70(age ≥16y) or Lansky Score ≥ 50(age\\\u003C16y).\n* TCR-T cell donor inclusion criteria: 1) Age 8-70 years; 2) Understand and voluntarily sign informed consent and are willing to comply with laboratory tests and other research procedures; 3) ≥ 3\u002F6 HLA match with TCR-T cell recipients enrolled; 4) Lymphocyte count = (0.8\\~4) × 10\\^9\u002FL; 5) Have sufficient venous circulation, without any symptoms that do not allow blood cell isolation.\n\nExclusion Criteria:\n\n* Patients with uncontrolled active aGVHD one day before TCR-T cell infusion.\n* Patients with severe kidney disease (Cr \\> 3×normal value), liver damage (TBIL \\>2.5×upper limit of normal value, ALT and AST \\> 3×upper limit of normal value) or heart failure (NYHA heart function grade IV) one week before TCR-T cell infusion.\n* Anticipated to take immunosuppressive hormones on the day of TCR-T cell infusion.\n* Have other malignancies.\n* Have relapsed and uncontrolled hematologic malignancies.\n* Serologically positive for HIV-Ab or TAP-ab.\n* Pregnant or lactating women.\n* Anticipated to have other cell therapies in 4 week post TCR-T cell infusion.\n* Participated in any other clinical study of drugs and medical devices before 30 days of enrollment.","ALL","14 Years","75 Years",{"count":67,"type":68},12,"ESTIMATED","INTERVENTIONAL",[71],"PHASE1","This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of EBV-TCR-T cell immunotherapy in treating EBV virus infection after allogenic HSCT.",[74],"EBV Infection After Allogenic HSCT",[76,77],"EBV infection","allogenic HSCT","2026-03-29",{"date":80,"type":81},"2026-04-02","ACTUAL",{"date":83,"type":81},"2023-08-01",{"date":85,"type":68},"2028-12-31",{"name":5,"class":6},1]